



Program

WORLD CONGRESS ON CONTROVERSIES IN
OBESITY AND DIABETES
THE FUTURE OF OBESITY
AND DIABETES 2025-2030

28-29 October 2024 | Tel Aviv, Israel



ההרצאות של הכנס הינן בעברית למעט המרצים מחו"ל
All lectures will be in Hebrew except the speakers from abroad

Monday, 28 October 2024

08:00-09:00	Registration & Welcome Refreshments
HALL A	
09:00-09:10	Opening Remarks & Welcome <i>Prof. Itamar Raz, Israel</i> <i>Prof. Stefano Del Prato, Italy</i> 
09:10-11:10	Session 1: Present and Future in the Treatment of Obesity and Diabetes <i>Chairs: Prof. Stefano Del Prato, Italy</i>  <i>Prof. Jaakko Tuomilehto, Finland</i> 
09:10-09:40	Obesity, State of the Art Sponsored by Novo Nordisk <i>Dr. David Macklin, University of Toronto & MedCan Clinic, Canada</i>
09:40-10:10	Prevention of Type 2 Diabetes <i>Prof. Jaakko Tuomilehto, University of Helsinki, Finland</i> 
10:10-10:40	Cure <i>Prof. Stefano Del Prato, University of Pisa & Azienda Ospedaliero-Universitaria Pisana, Italy</i> 
10:40-11:10	Roundtable Discussion
11:10-11:40	Refreshments, Networking & Visit the Exhibition

HALL A		HALL B	
11:40-13:10	Session 2: Obesity Session Taking the next STEP in obesity treatment Sponsored by Novo Nordisk <i>Symposium Moderator: Prof. Itamar Raz, Chairman of the Diabetes National Council, Israel</i>	11:40-13:10	Session 3: Prevention and Treatment of Target Organs <i>Chairs: Prof. Edo Birati, Israel</i> <i>Dr. Gil Chernin, Israel</i>
Obesity Management, is Much More than Weight Loss <i>Dr. Yoel Toledano, Beilinson Hospital, Israel</i> SELECT, Breakthrough in Obesity and CVD <i>Prof. Michael Shechter, Sheba Medical Center, Israel</i> Practical Tools in Obesity Management <i>Dr. Dan Oieru, Maccabi Healthcare Services, Israel</i>		11:40-11:50	Introduction <i>Prof. Rifaat Safadi, Hadassah University Hospital, Israel</i>
		11:50-12:10	The Kidney Bayer Independent Sponsorship <i>Dr. Gil Chernin, Kaplan Medical Center, Israel</i>
		12:10-12:30	The Liver <i>Prof. Rifaat Safadi, Hadassah University Hospital, Israel</i>

		12:30-12:50	The Cardiovascular System Boehringer Ingelheim Independent Sponsorship <i>Prof. Edo Birati, Tzafon Medical Center, Israel</i>
		12:50-13:10	Roundtable Discussion
13:10-13:30	Short Coffee Break, Networking & Visit the Exhibition		
13:30-15:00	Session 4: Inflammation in Obesity and Diabetes <i>Chair: Prof. Naftali Stern, Israel</i> <i>Prof. Assaf Rudich, Israel</i>	13:30-15:00	Session 5: AI in the Prevention and treatment of obesity and diabetes <i>Chairs: Dr. Eran Segal, Israel</i> <i>Prof. Eberhard Standl, Germany</i> 🇩🇪
13:30-13:40	Introduction <i>Prof. Naftali Stern, Tel Aviv Sourasky Medical Center, Israel</i>	13:30-13:40	Introduction <i>Dr. Eran Segal, Clalit Healthcare Services, Israel</i>
13:40-14:00	Adipose Tissue Inflammation: A Way to Personalize Obesity Care? <i>Prof. Assaf Rudich, Ben-Gurion University of the Negev, Israel</i>	13:40-14:00	Obesity <i>Dr. Eran Segal, Clalit Healthcare Services, Israel</i>
14:00-14:20	The Genital System <i>Dr. Roni Weinberg Sibony, Meir Medical Center Hospital, Israel</i>	14:00-14:20	Diabetes <i>Prof. Eugene Merzon, Leumit Health Services, Israel</i>
14:20-14:40	The Brain <i>Prof. Naftali Stern, Tel Aviv Sourasky Medical Center, Israel</i>	14:20-14:40	Target Organs <i>Prof. Eberhard Standl, Diabetes Research Group, Munich Helmholtz Centre, Germany</i> 🇩🇪
14:40-15:00	Roundtable Discussion	14:40-15:00	Roundtable Discussion
15:00-16:00	Lunch Break, Networking & Visit the Exhibition		
16:00	End of Day One		

ג'ארדיאנס זמין למטופלים שלך בסל הבריאות 2024¹⁻²



HF

זמין לרישום דרך סל הבריאות²

לחולי אי ספיקת לב^{^^}

עם מקטע פליטה ירוד $LVEF \leq 40\%$ אשר נותר סימפטומטיים למרות מיצוי טיפול מיטבי למחלתם. לעניין זה טיפול מיטבי יכולול תרופות ממשפחת ACE/ARB, BB מעכבי

עם מקטע פליטה שמור $LVEF > 40\%$

וגם

NYHA class II-IV



CKD

זמין לרישום דרך סל הבריאות²

לחולי מחלת כליה כרונית^{^^}

המטופלים ב- ACEi/ARB ועונים על אחד מאלה^{^^}:

$45 \leq eGFR \leq 90$ ml/min/1.73m²
UACR ≥ 200 mg/g וגם

או

$20 \leq eGFR \leq 45$ ml/min/1.73m²

ללא תלות בערכי יחס אלבומין/קראטינין (UACR) בשתן

** בהתאם לתנאי הרישום



T2D

זמין לרישום דרך סל הבריאות²

לחולי סוכרת סוג 2[¥]

$HbA1c \geq 7\%$ על אף טיפול קודם למחלתם
 $eGFR \geq 30$ mL/min/1.73m²**

ובנוסף אבחנה של אחד מאלה:

מטופל עם מחלה קרדיאלית אוטם בשריר הלב או ניתוח מעקפים או מחלת לב איסכמית

מטופל עם מחלה כלייתית

$eGFR < 60$ mL/min/1.73m²
או UACR > 30 mg/g

טיפול בסוכרת סוג 2 בילדים בני 10 שנים ומעלה^{^^}

** בהתאם לתנאי הרישום

למטופל שאינו עונה על קריטריוני הסל ג'ארדיאנס זמין לרישום:

- דרך הביטוחים המשלימים של כל קופות החולים בהשתתפות הקופה • סופרפארם - במחיר מיוחד במתן מרשם פרטי

1. JARDIANCE® Israeli Prescribing Information 2, 2024 מרץ 2024. עדכון סל התרופות, מרץ 2024.

LVEF=left ventricular ejection Fraction; NYHA=New York Heart Association; eGFR=estimated glomerular filtration rate; UACR= urinary albumin to creatinine ratio; ACEi= Angiotensin-converting-enzyme inhibitors; ARB= angiotensin receptor blocker; BB= Beta Blockers ¥ JARDIANCE is not recommended for use to improve glycaemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m2. JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action. ^^ Due to limited experience, it is not recommended to initiate treatment with empagliflozin in patients with eGFR < 20 mL/min/1.73 m2

For more information, please refer to the full MoH approved prescribing information located at the IL MOH website: <https://israeldrugs.health.gov.il/#/byDrug>

Jardiance (empagliflozin) 10 mg and 25 mg of film-coated tablets. JARDIANCE 10mg and 25mg is indicated: • as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. • to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. JARDIANCE 10mg is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. • to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. • as an adjunct to diet and exercise to improve glycaemic control in pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use: • JARDIANCE is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. • JARDIANCE is not recommended for use to improve glycaemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m2. JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action • JARDIANCE is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. JARDIANCE is not expected to be effective in these populations. Contraindications: hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, reactions such as angioedema have occurred. Most Common Adverse events: The most common adverse reactions associated with the use of JARDIANCE are: hypoglycemia, Urinary tract infection, Female genital mycotic infections, Upper respiratory tract infection, Increased urination, Dyslipidemia, Arthralgia, Male genital mycotic infections and Nausea. Marketing authorization holder: Boehringer Ingelheim Israel Ltd. Medinat Ha-Yehudim 89 St. P. Box 4124 Herzliya Pituach 4676672 Copyright © 2024 Boehringer Ingelheim Israel Ltd. All rights reserved. | PC-IL-102643

Tuesday, 29 October 2024

HALL A		HALL B	
08:00-09:00	Registration & Welcome Refreshments		
09:00-10:50	Session 6: Obesity <i>Chairs: Prof. Stefano Del Prato, Italy</i>  <i>Prof. Naftali Stern, Israel</i>	09:00-10:50	Session 7: Type 1 Diabetes: Future Technologies <i>Chairs: Prof. Ram Weiss, Israel</i> <i>Dr. Eytan Roitman, Israel</i>
09:00-09:10	Introduction <i>Prof. Dror Dicker, Hasharon Hospital, Rabin Medical Center, Israel</i>	09:00-09:10	Introduction <i>Prof. Itamar Raz, Chairman of the Diabetes National Council, Israel</i>
09:10-09:30	Diagnoses, Prevention and Treatment <i>Prof. Dror Dicker, Hasharon Hospital, Rabin Medical Center, Israel</i>	09:10-09:30	Off Label Treatment for Type 1 Diabetes Abbott Independent Sponsorship <i>Prof. Ram Weiss, Rambam Medical Center, Israel</i>
09:30-09:50	The Metabolic Effects of Intermittent Fasting in Obesity <i>Prof. Naftali Stern, Tel Aviv Sourasky Medical Center, Israel</i>	09:30-09:50	New Treatments Emerging for Type 1 Diabetes <i>Dr. Eytan Roitman, Clalit Healthcare Services, Israel</i>
09:50-10:10	Complications <i>Prof. Eberhard Standl, Diabetes Research Group, Munich Helmholtz Centre, Germany</i> 	09:50-10:10	Cure for Type 1 Diabetes <i>Prof. Paolo Pozzilli, Campus Bio-Medico University of Rome, Italy & St. Bartholomew's and London School of Medicine, Queen Mary University of London, UK</i> 
10:10-10:50	Roundtable Discussion	10:10-10:50	Roundtable Discussion
10:50-11:20	Refreshments, Networking & Visit the Exhibition		

11:20-13:00	Session 8: Microbiome in Obesity and Diabetes <i>Chair: Dr. Hagit Shapiro, Israel</i> <i>Dr. Idit Dotan, Israel</i>	11:20-12:35	Session 9: Obesity and Diabetes
11:20-11:30	Introduction <i>Prof. Jaakko Tuomilehto, University of Helsinki, Finland</i> 🇫🇮	11:20-12:35	Integrated Management of Cardio-Renal Metabolic Complications in Type 2 Diabetes Patients Sponsored by Novo Nordisk Symposium Moderator: Prof. Itamar Raz, Chairman of the Diabetes National Council, Israel
11:30-11:50	Microbiome in Obesity / the place of Probiotic <i>Dr. Hagit Shapiro, Weizmann Institute of Science, Israel</i>		Cardiovascular Risk Management in Type 2 Diabetes Patients - Current Strategies and Future Directions <i>Prof. Yaron Arbel, Tel Aviv Medical Center, Israel</i>
11:50-12:10	Microbiome in Diabetes / the place of Probiotic <i>Prof. Jaakko Tuomilehto, University of Helsinki, Finland</i> 🇫🇮	12:35-12:55	Treatment of Diabetes Retinopathy Present and Future Roche Independent Sponsorship <i>Dr. Cornelius Nasser, Shamir Medical Center, Israel</i>
12:10-12:30	Reduction of Cardiovascular Risk – Closing the TG Gap Neopharm Independent Sponsorship <i>Dr. Idit Dotan, Rabin Medical Center, Israel</i>		
12:30-13:00	Roundtable Discussion		
13:00-13:20	Coffee Break, Networking & Visit the Exhibition		

13:20-14:30	Session 10: Drugs Vs Bariatric Surgery in Obesity <i>Chair: Prof. Itamar Raz, Israel</i> <i>Prof. Dror Dicker, Israel</i>	13:20-14:30	Session 11: Longevity <i>Chair: Prof. Tzipi Strauss, Israel</i>
13:20-13:30	Introduction <i>Prof. Itamar Raz, Chairman of the Diabetes National Council, Israel</i>	13:20-13:30	Introduction <i>Prof. Nir Barzilai, Albert Einstein College of Medicine, USA</i> 🇺🇸
13:30-13:50	Drugs in Obesity <i>Prof. Luc Van Gaal, Antwerp University, Belgium</i> 🇧🇪	13:30-13:50	Longevity Diagnostic and Interventions <i>Prof. Tzipi Strauss, Sheba Medical Center, Israel</i>
13:50-14:10	Obesity Management Medication Vs. Bariatric Metabolic Surgery, What is the evidence? <i>Prof. Dror Dicker, Hasharon Hospital, Rabin Medical Center, Israel</i>	13:50-14:10	Biomarkers of Healthy Longevity Medicine <i>Prof. Evelyne Bischof, Sheba Medical Center, Israel</i> 🇮🇱
14:10-14:30	Roundtable Discussion	14:10-14:30	Roundtable Discussion
14:30-14:35	Short Break	14:30-14:35	Short Break
14:35-14:50	Congress Summary & Closing Remarks <i>Prof. Itamar Raz, Israel</i>		
14:50-15:50	Lunch Break, Networking & Visit the Exhibition		
15:50	End of Congress		

Platinum Sponsor



Diamond Sponsor



Sponsors



Boehringer
Ingelheim



Abbott



J&J MedTech Israel

Exhibitors

